AIMS: To determine the risk of age-related macular degeneration (AMD) progression posed by the presence of each early AMD characteristic. METHODS: A prospective cohort study of 254 participants aged 50 years and older, all with early AMD features at their baseline visit followed for an average of 7 years. Stereoscopic colour fundus photographs were graded for early AMD features using the International Classification System. AMD status was stratified into six exclusive levels along a continuum of disease severity according to drusen type, pigmentary abnormalities, or late AMD. Progression was assessed according to three definitions: a change between or within a severity level, or by side by side grading. RESULTS: The progression rate of early AMD ranged between 3.4 and 4.67% per annum depending upon the definition used. In total, 15 (6%) cases progressed from early AMD to the late complication of AMD. After controlling for age and smoking, cases with soft indistinct drusen at baseline were at a greater risk of progressing from early to late AMD than were cases without this characteristic (OR=3.72, 95%CI 1.20-11.54; P=0.02). CONCLUSION: Our proposed definitions of AMD progression give rates that are consistent with current knowledge of progression and its determinants. Each early AMD characteristic conveys its own risk of progression to an eye, with soft indistinct drusen carrying the greater risk. An international consensus on what defines AMD progression would greatly help the research community when trying to assess the importance of new risk factors and the effectiveness of novel interventions.
AIMS: To determine the risk of age-related macular degeneration (AMD) progression posed by the presence of each early AMD characteristic. METHODS: A prospective cohort study of 254 participants aged 50 years and older, all with early AMD features at their baseline visit followed for an average of 7 years. Stereoscopic colour fundus photographs were graded for early AMD features using the International Classification System. AMD status was stratified into six exclusive levels along a continuum of disease severity according to drusen type, pigmentary abnormalities, or late AMD. Progression was assessed according to three definitions: a change between or within a severity level, or by side by side grading. RESULTS: The progression rate of early AMD ranged between 3.4 and 4.67% per annum depending upon the definition used. In total, 15 (6%) cases progressed from early AMD to the late complication of AMD. After controlling for age and smoking, cases with soft indistinct drusen at baseline were at a greater risk of progressing from early to late AMD than were cases without this characteristic (OR=3.72, 95%CI 1.20-11.54; P=0.02). CONCLUSION: Our proposed definitions of AMD progression give rates that are consistent with current knowledge of progression and its determinants. Each early AMD characteristic conveys its own risk of progression to an eye, with soft indistinct drusen carrying the greater risk. An international consensus on what defines AMD progression would greatly help the research community when trying to assess the importance of new risk factors and the effectiveness of novel interventions.
Authors: G Silvestri; M A Williams; C McAuley; K Oakes; E Sillery; D C Henderson; S Ferguson; V Silvestri; K A Muldrew Journal: Eye (Lond) Date: 2012-08-17 Impact factor: 3.775
Authors: Jessica N Cooke Bailey; Margaret A Pericak-Vance; Jonathan L Haines Journal: Cold Spring Harb Perspect Med Date: 2014-09-11 Impact factor: 6.915
Authors: Rebecca J Sardell; Muneeswar G Nittala; Larry D Adams; Reneé A Laux; Jessica N Cooke Bailey; Denise Fuzzell; Sarada Fuzzell; Lori Reinhart-Mercer; Laura J Caywood; Violet Horst; Tine Mackay; Debbie Dana; SriniVas R Sadda; William K Scott; Dwight Stambolian; Jonathan L Haines; Margaret A Pericak-Vance Journal: Ophthalmology Date: 2016-10-19 Impact factor: 12.079
Authors: Lars G Fritsche; Robert N Fariss; Dwight Stambolian; Gonçalo R Abecasis; Christine A Curcio; Anand Swaroop Journal: Annu Rev Genomics Hum Genet Date: 2014-04-16 Impact factor: 8.929
Authors: Laura S Frost; Vanda S Lopes; Frank P Stefano; Alvina Bragin; David S Williams; Claire H Mitchell; Kathleen Boesze-Battaglia Journal: Vis Neurosci Date: 2013-04-23 Impact factor: 3.241
Authors: Amy B Karger; Weihua Guan; Sarah O Nomura; Natalie L Weir; Barbara E K Klein; Gregory L Burke; W Craig Johnson; Michael Y Tsai Journal: Retina Date: 2022-07-01 Impact factor: 3.975
Authors: Muneeswar G Nittala; Yeunjoo E Song; Rebecca Sardell; Larry D Adams; Samuel Pan; Swetha B Velaga; Violet Horst; Debra Dana; Laura Caywood; Renee Laux; Denise Fuzzell; Sarada Fuzzell; William K Scott; Jessica N Cooke Bailey; Robert P Igo; Jonathan Haines; Margaret A Pericak-Vance; SriniVas R Sadda; Dwight Stambolian Journal: Retina Date: 2019-08 Impact factor: 3.975
Authors: Catherine A McCarty; Adam Dowrick; James Cameron; Barry McGrath; Luba D Robman; Peter Dimitrov; Gabriella Tikellis; Caroline Nicolas; John McNeil; Robyn Guymer Journal: BMC Ophthalmol Date: 2008-12-22 Impact factor: 2.209
Authors: Robyn H Guymer; Peter N Dimitrov; Mary Varsamidis; Lyndell L Lim; Paul N Baird; Algis J Vingrys; Luba Robman Journal: Clin Interv Aging Date: 2008 Impact factor: 4.458